HealthFirst Talks: Safeguarding Our Air against Viruses and other Pathogens

 

The COVID-19 pandemic has thrust air quality into the spotlight, particularly in the spaces we inhabit most, such as our homes, workplaces, schools and more.

Fortunately, there are lines of defense against airborne viruses and pathogens. To explore those solutions, Dr. Scott A. Cohen of Bassett Healthcare Network and infection prevention specialist Dr. Fiona Collins joined this episode of HealthFirst Talks.

There are many aspects of an effective strategy for improving air quality – along with many considerations, such as dosage exposure to actually become infected and more.

“Some researchers have estimated that it takes about 300 particles to become infected. Typically, it’s about 2,000 to 3,000 for other viruses. So, if you think about it, it’s really highly infectious,” Cohen said. “Honestly, when we think about this, it really just helps us figure out what we need to do to decrease the risk of getting exposed.”

Because monitoring the air for aerosols and concentrations of the virus is expensive and impractical, the use of proxies as a better benchmark for understanding how safe a space is. For example, outdoor carbon dioxide levels are about 415 million parts per million, mainly due to fossil fuels. Indoor counts can be closer to 800-1,200 parts per million, providing a benchmark that can inform you about a space’s overall ventilation capabilities.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…